

Stephano Monti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6881718/publications.pdf>

Version: 2024-02-01

99
papers

14,712
citations

50276

46
h-index

32842

100
g-index

118
all docs

118
docs citations

118
times ranked

22428
citing authors

#	ARTICLE	IF	CITATIONS
1	Title is missing!. Machine Learning, 2003, 52, 91-118.	5.4	1,613
2	Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-472.	27.8	1,288
3	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 2018, 24, 679-690.	30.7	1,224
4	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010, 116, 3268-3277.	1.4	1,122
5	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 2003, 102, 3871-3879.	1.4	793
6	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 2005, 105, 1851-1861.	1.4	778
7	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell, 2013, 24, 777-790.	16.8	635
8	Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis and Rheumatism, 2005, 52, 2926-2935.	6.7	592
9	Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016, 127, 869-881.	1.4	429
10	Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 22, 547-560.	16.8	422
11	Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. Cell, 2011, 147, 107-119.	28.9	411
12	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. Journal of Experimental Medicine, 2006, 203, 311-317.	8.5	326
13	The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13134-13139.	7.1	299
14	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood, 2008, 111, 2230-2237.	1.4	289
15	Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts. Journal of Clinical Oncology, 2006, 24, 5079-5090.	1.6	263
16	NF- κ B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood, 2005, 106, 1392-1399.	1.4	229
17	Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 22, 359-372.	16.8	179
18	Renal Involvement in Churg-Strauss Syndrome. American Journal of Kidney Diseases, 2006, 47, 770-779.	1.9	169

#	ARTICLE	IF	CITATIONS
19	Nonlinear partial differential equations and applications: Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15468-15473.	7.1	156
20	SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas. Cancer Cell, 2013, 23, 826-838.	16.8	152
21	Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas. PLoS ONE, 2012, 7, e33813.	2.5	137
22	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3207-3212.	7.1	130
23	An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER ⁺ /PR ⁺ /Her2 ⁺ Human Breast Cancer Cells. Molecular Pharmacology, 2016, 90, 674-688.	2.3	124
24	Comparative gene marker selection suite. Bioinformatics, 2006, 22, 1924-1925.	4.1	123
25	The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood, 2013, 122, 376-385.	1.4	119
26	hyperR: an R package for geneset enrichment workflows. Bioinformatics, 2020, 36, 1307-1308.	4.1	117
27	Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood, 2007, 110, 3015-3027.	1.4	115
28	Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth <i>In Vitro</i> and <i>In Vivo</i> . Clinical Cancer Research, 2014, 20, 2674-2683.	7.0	114
29	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Research, 2006, 66, 11389-11398.	0.9	112
30	A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma. Molecular Cancer Research, 2015, 13, 957-968.	3.4	107
31	The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. BMC Biology, 2016, 14, 20.	3.8	80
32	Altered RNA editing in 3' UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Scientific Reports, 2016, 6, 23226.	3.3	77
33	Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood, 2011, 117, 4315-4322.	1.4	75
34	Pathways of Toxicity. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 53-61.	1.5	75
35	Genomic Models of Short-Term Exposure Accurately Predict Long-Term Chemical Carcinogenicity and Identify Putative Mechanisms of Action. PLoS ONE, 2014, 9, e102579.	2.5	72
36	Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells. EMBO Reports, 2018, 19, .	4.5	70

#	ARTICLE	IF	CITATIONS
37	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. <i>Blood</i> , 2016, 127, 2203-2213.	1.4	68
38	RNA Binding and Core Complexes Constitute the U-Insertion/Deletion Editosome. <i>Molecular and Cellular Biology</i> , 2014, 34, 4329-4342.	2.3	67
39	Role for the Aryl Hydrocarbon Receptor and Diverse Ligands in Oral Squamous Cell Carcinoma Migration and Tumorigenesis. <i>Molecular Cancer Research</i> , 2016, 14, 696-706.	3.4	67
40	A Transcriptional Profiling Study of CCAAT/Enhancer Binding Protein Targets Identifies Hepatocyte Nuclear Factor 3 β as a Novel Tumor Suppressor in Lung Cancer. <i>Cancer Research</i> , 2004, 64, 4137-4147.	0.9	66
41	The role of the aryl hydrocarbon receptor in normal and malignant B cell development. <i>Seminars in Immunopathology</i> , 2013, 35, 705-716.	6.1	63
42	Respiratory Failure Due to Differentiation Arrest and Expansion of Alveolar Cells following Lung-Specific Loss of the Transcription Factor C/EBP β in Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 1109-1123.	2.3	61
43	Yap suppresses T-cell function and infiltration in the tumor microenvironment. <i>PLoS Biology</i> , 2020, 18, e3000591.	5.6	58
44	How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 387.	4.1	54
45	Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. <i>Blood</i> , 2008, 112, 1981-1992.	1.4	51
46	Predicting dire outcomes of patients with community acquired pneumonia. <i>Journal of Biomedical Informatics</i> , 2005, 38, 347-366.	4.3	50
47	Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2873-2878.	7.1	49
48	Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations. <i>Scientific Reports</i> , 2018, 8, 3010.	3.3	48
49	Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1388.	4.1	45
50	Thyroid Progenitors Are Robustly Derived from Embryonic Stem Cells through Transient, Developmental Stage-Specific Overexpression of Nr α 2-1. <i>Stem Cell Reports</i> , 2017, 8, 216-225.	4.8	44
51	Functional and genomic analyses reveal therapeutic potential of targeting β -catenin/CBP activity in head and neck cancer. <i>Genome Medicine</i> , 2018, 10, 54.	8.2	43
52	Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. <i>Oncotarget</i> , 2017, 8, 73372-73386.	1.8	43
53	Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis. <i>Stem Cell Reports</i> , 2013, 1, 451-463.	4.8	42
54	15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3 β and a Tumor Suppressor in Lung Cancer. <i>Cancer Research</i> , 2008, 68, 5040-5048.	0.9	40

#	ARTICLE	IF	CITATIONS
55	FAS Death Domain Deletions and Cellular FADD-like Interleukin 1 ^{Î²} Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes. <i>Clinical Cancer Research</i> , 2006, 12, 3265-3271.	7.0	37
56	Antisense Transcripts Delimit Exonucleolytic Activity of the Mitochondrial 3 ^{â€²} Processome to Generate Guide RNAs. <i>Molecular Cell</i> , 2016, 61, 364-378.	9.7	35
57	Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. <i>Oncotarget</i> , 2016, 7, 33316-33330.	1.8	35
58	Assessment of microRNA differential expression and detection in multiplexed small RNA sequencing data. <i>Rna</i> , 2015, 21, 164-171.	3.5	31
59	PDGFR ^{Î²} Is a Novel Marker of Stromal Activation in Oral Squamous Cell Carcinomas. <i>PLoS ONE</i> , 2016, 11, e0154645.	2.5	31
60	Inhibition of Ubc13-mediated Ubiquitination by GPS2 Regulates Multiple Stages of B Cell Development. <i>Journal of Biological Chemistry</i> , 2017, 292, 2754-2772.	3.4	30
61	Bayesian Methods for Multivariate Modeling of Pleiotropic SNP Associations and Genetic Risk Prediction. <i>Frontiers in Genetics</i> , 2012, 3, 176.	2.3	28
62	ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways. <i>Bioinformatics</i> , 2015, 31, 1745-1753.	4.1	28
63	Pipeliner: A Nextflow-Based Framework for the Definition of Sequencing Data Processing Pipelines. <i>Frontiers in Genetics</i> , 2019, 10, 614.	2.3	28
64	A serum protein signature of <i>APOE</i> genotypes in centenarians. <i>Aging Cell</i> , 2019, 18, e13023.	6.7	27
65	Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 19-30.	2.8	25
66	Yap/Taz inhibit goblet cell fate to maintain lung epithelial homeostasis. <i>Cell Reports</i> , 2021, 36, 109347.	6.4	24
67	Tributyltin induces a transcriptional response without a brite adipocyte signature in adipocyte models. <i>Archives of Toxicology</i> , 2018, 92, 2859-2874.	4.2	23
68	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. <i>Haematologica</i> , 2020, 105, 1361-1368.	3.5	23
69	<sc>PPR</sc> polyadenylation factor defines mitochondrial <sc>mRNA</sc> identity and stability in trypanosomes. <i>EMBO Journal</i> , 2017, 36, 2435-2454.	7.8	20
70	The Carcinome Project: <i>In Vitro</i> Gene Expression Profiling of Chemical Perturbations to Predict Long-Term Carcinogenicity. <i>Environmental Health Perspectives</i> , 2019, 127, 47002.	6.0	20
71	Naturally occurring hotspot cancer mutations in GÎ±13 promote oncogenic signaling. <i>Journal of Biological Chemistry</i> , 2020, 295, 16897-16904.	3.4	19
72	animalcules: interactive microbiome analytics and visualization in R. <i>Microbiome</i> , 2021, 9, 76.	11.1	18

#	ARTICLE	IF	CITATIONS
73	Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma. <i>Blood</i> , 2006, 107, 844-845.	1.4	17
74	Network-based analysis of transcriptional profiles from chemical perturbations experiments. <i>BMC Bioinformatics</i> , 2017, 18, 130.	2.6	17
75	Learning Bayesian Networks from Correlated Data. <i>Scientific Reports</i> , 2016, 6, 25156.	3.3	16
76	The diverse and important contributions of the AHR to cancer and cancer immunity. <i>Current Opinion in Toxicology</i> , 2017, 2, 93-102.	5.0	14
77	β -Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma. <i>Molecular Omics</i> , 2020, 16, 195-209.	2.8	14
78	Effect of longevity genetic variants on the molecular aging rate. <i>GeroScience</i> , 2021, 43, 1237-1251.	4.6	12
79	Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition. <i>Molecular Cancer Research</i> , 2022, 20, 712-721.	3.4	12
80	Loss of G-Protein Pathway Suppressor 2 Promotes Tumor Growth Through Activation of AKT Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 608044.	3.7	10
81	Bounded recursive decomposition: a search-based method for belief-network inference under limited resources. <i>International Journal of Approximate Reasoning</i> , 1996, 15, 49-75.	3.3	9
82	Gene expression alterations in salivary gland epithelia of Sjögren's syndrome patients are associated with clinical and histopathological manifestations. <i>Scientific Reports</i> , 2021, 11, 11154.	3.3	9
83	Contextualized Protein-Protein Interactions. <i>Patterns</i> , 2021, 2, 100153.	5.9	8
84	A Data-Driven Transcriptional Taxonomy of Adipogenic Chemicals to Identify White and Brite Adipogens. <i>Environmental Health Perspectives</i> , 2021, 129, 77006.	6.0	7
85	CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features. <i>Frontiers in Genetics</i> , 2019, 10, 121.	2.3	6
86	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. <i>Blood</i> , 2015, 126, 817-817.	1.4	5
87	Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies. <i>Diabetes Care</i> , 2022, 45, 1882-1892.	8.6	5
88	Assessment of a Highly Multiplexed RNA Sequencing Platform and Comparison to Existing High-Throughput Gene Expression Profiling Techniques. <i>Frontiers in Genetics</i> , 2019, 10, 150.	2.3	4
89	Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis. <i>Scientific Reports</i> , 2019, 9, 16904.	3.3	4
90	Multi-resolution characterization of molecular taxonomies in bulk and single-cell transcriptomics data. <i>Nucleic Acids Research</i> , 2021, 49, e98-e98.	14.5	4

#	ARTICLE	IF	CITATIONS
91	SimFuse: A Novel Fusion Simulator for RNA Sequencing (RNA-Seq) Data. BioMed Research International, 2015, 2015, 1-5.	1.9	3
92	PopCluster: an algorithm to identify genetic variants with ethnicity-dependent effects. Bioinformatics, 2019, 35, 3046-3054.	4.1	3
93	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. Blood, 2014, 124, 74-74.	1.4	2
94	An information-based bayesian approach to history taking. Lecture Notes in Computer Science, 1995, , 127-138.	1.3	2
95	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 3021-3021.	1.4	1
96	Preclinical Analyses Of The Chemical JAK2 Inhibitor, SAR302503, In Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. Blood, 2013, 122, 4230-4230.	1.4	1
97	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 631-631.	1.4	1
98	Resolving the Biological Heterogeneity of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and BL (BCL-U) Using Quantitative Profiles of Oncogenic Signaling Networks. Blood, 2015, 126, 3903-3903.	1.4	0
99	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3922-3922.	1.4	0